182 related articles for article (PubMed ID: 38862983)
21. Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship.
Jhanwar-Uniyal M; Wainwright JV; Mohan AL; Tobias ME; Murali R; Gandhi CD; Schmidt MH
Adv Biol Regul; 2019 May; 72():51-62. PubMed ID: 31010692
[TBL] [Abstract][Full Text] [Related]
22. Distinct inhibitory effects on mTOR signaling by ethanol and INK128 in diffuse large B-cell lymphoma.
Mazan-Mamczarz K; Peroutka RJ; Steinhardt JJ; Gidoni M; Zhang Y; Lehrmann E; Landon AL; Dai B; Houng S; Muniandy PA; Efroni S; Becker KG; Gartenhaus RB
Cell Commun Signal; 2015 Mar; 13():15. PubMed ID: 25849580
[TBL] [Abstract][Full Text] [Related]
23. RES-529: a PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes.
Weinberg MA
Anticancer Drugs; 2016 Jul; 27(6):475-87. PubMed ID: 26918392
[TBL] [Abstract][Full Text] [Related]
24. Defining the role of mTOR pathway in the regulation of stem cells of glioblastoma.
Jhanwar-Uniyal M; Gellerson O; Bree J; Das M; Kleinman G; Gandhi CD
Adv Biol Regul; 2023 May; 88():100946. PubMed ID: 36658088
[TBL] [Abstract][Full Text] [Related]
25. Hypoxia Increases IGFBP-1 Phosphorylation Mediated by mTOR Inhibition.
Damerill I; Biggar KK; Abu Shehab M; Li SS; Jansson T; Gupta MB
Mol Endocrinol; 2016 Feb; 30(2):201-16. PubMed ID: 26714229
[TBL] [Abstract][Full Text] [Related]
26. SC06, a novel small molecule compound, displays preclinical activity against multiple myeloma by disrupting the mTOR signaling pathway.
Han K; Xu X; Xu Z; Chen G; Zeng Y; Zhang Z; Cao B; Kong Y; Tang X; Mao X
Sci Rep; 2015 Sep; 5():12809. PubMed ID: 26329846
[TBL] [Abstract][Full Text] [Related]
27. SCFFbxo9 and CK2 direct the cellular response to growth factor withdrawal via Tel2/Tti1 degradation and promote survival in multiple myeloma.
Fernández-Sáiz V; Targosz BS; Lemeer S; Eichner R; Langer C; Bullinger L; Reiter C; Slotta-Huspenina J; Schroeder S; Knorn AM; Kurutz J; Peschel C; Pagano M; Kuster B; Bassermann F
Nat Cell Biol; 2013 Jan; 15(1):72-81. PubMed ID: 23263282
[TBL] [Abstract][Full Text] [Related]
28. Regulation and metabolic functions of mTORC1 and mTORC2.
Szwed A; Kim E; Jacinto E
Physiol Rev; 2021 Jul; 101(3):1371-1426. PubMed ID: 33599151
[TBL] [Abstract][Full Text] [Related]
29. Structural mechanisms of the mTOR pathway.
Linde-Garelli KY; Rogala KB
Curr Opin Struct Biol; 2023 Oct; 82():102663. PubMed ID: 37572585
[TBL] [Abstract][Full Text] [Related]
30. RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.
Gordon BS; Kazi AA; Coleman CS; Dennis MD; Chau V; Jefferson LS; Kimball SR
Cell Signal; 2014 Mar; 26(3):461-7. PubMed ID: 24316235
[TBL] [Abstract][Full Text] [Related]
31. mTOR as a Potential Target for the Treatment of Microbial Infections, Inflammatory Bowel Diseases, and Colorectal Cancer.
Afzal O; Altamimi ASA; Mubeen B; Alzarea SI; Almalki WH; Al-Qahtani SD; Atiya EM; Al-Abbasi FA; Ali F; Ullah I; Nadeem MS; Kazmi I
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293326
[TBL] [Abstract][Full Text] [Related]
32. Targeting the mTOR pathway in tumor malignancy.
Cheng H; Walls M; Baxi SM; Yin MJ
Curr Cancer Drug Targets; 2013 Mar; 13(3):267-77. PubMed ID: 23297825
[TBL] [Abstract][Full Text] [Related]
33. Current development of the second generation of mTOR inhibitors as anticancer agents.
Zhou HY; Huang SL
Chin J Cancer; 2012 Jan; 31(1):8-18. PubMed ID: 22059905
[TBL] [Abstract][Full Text] [Related]
34. Nutrient signaling to mTOR and cell growth.
Jewell JL; Guan KL
Trends Biochem Sci; 2013 May; 38(5):233-42. PubMed ID: 23465396
[TBL] [Abstract][Full Text] [Related]
35. Metformin induces autophagy and G0/G1 phase cell cycle arrest in myeloma by targeting the AMPK/mTORC1 and mTORC2 pathways.
Wang Y; Xu W; Yan Z; Zhao W; Mi J; Li J; Yan H
J Exp Clin Cancer Res; 2018 Mar; 37(1):63. PubMed ID: 29554968
[TBL] [Abstract][Full Text] [Related]
36. AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
Guichard SM; Curwen J; Bihani T; D'Cruz CM; Yates JW; Grondine M; Howard Z; Davies BR; Bigley G; Klinowska T; Pike KG; Pass M; Chresta CM; Polanska UM; McEwen R; Delpuech O; Green S; Cosulich SC
Mol Cancer Ther; 2015 Nov; 14(11):2508-18. PubMed ID: 26358751
[TBL] [Abstract][Full Text] [Related]
37. Using
Frappaolo A; Giansanti MG
Cells; 2023 Nov; 12(22):. PubMed ID: 37998357
[TBL] [Abstract][Full Text] [Related]
38. The PP242 mammalian target of rapamycin (mTOR) inhibitor activates extracellular signal-regulated kinase (ERK) in multiple myeloma cells via a target of rapamycin complex 1 (TORC1)/eukaryotic translation initiation factor 4E (eIF-4E)/RAF pathway and activation is a mechanism of resistance.
Hoang B; Benavides A; Shi Y; Yang Y; Frost P; Gera J; Lichtenstein A
J Biol Chem; 2012 Jun; 287(26):21796-805. PubMed ID: 22556409
[TBL] [Abstract][Full Text] [Related]
39. Second Generation mTOR Inhibitors as a Double-Edged Sword in Malignant Glioma Treatment.
Heinzen D; Divé I; Lorenz NI; Luger AL; Steinbach JP; Ronellenfitsch MW
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31510109
[TBL] [Abstract][Full Text] [Related]
40. Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.
Hussain AR; Al-Romaizan M; Ahmed M; Thangavel S; Al-Dayel F; Beg S; Uddin S; Siraj AK; Al-Kuraya KS
Mol Med; 2015 May; 21(1):466-78. PubMed ID: 26023849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
